# A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

> **NCT03277755** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** AL-335 800 mg
- **DRUG:** ODV 25 mg
- **DRUG:** SMV 75 mg

## Key facts

- **NCT ID:** NCT03277755
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-11
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development program of JNJ-4178 was discontinued.
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277755, "A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03277755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*